Emcure Pharmaceuticals Limited - Company Profile

It is a pharma public limited company based in Pune City, Maharashtra, India, established in 1981.
1981 Pune City, Maharashtra, India Active
Last Updated:
Access Report
About Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited, a active public limited company, was established on 16 April 1981 in Pune City, Maharashtra, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: L24231PN1981PLC024251. Registered under ROC Roc Pune. it is listed. It has an authorized capital of ₹250.00 Cr and a paid-up capital of ₹189.57 Cr.

Formerly known as Emcure Pharmaceuticals Private Limited. It upholds a compliant status. In 2024, it reported revenue of ₹3,635.91 Cr and a net worth of ₹1,935.10 Cr. Employing 6,877 professional, Its leadership includes Shailesh Kripalu Ayyangar (Director), Vijay Keshav Gokhale (Director), Berjis Minoo Desai (Director). Past directors included Amit Dixit, Mathew Cyriac, Jose Valentim Sartarelli. It holds ₹1,881.89 Cr open charges and ₹7,024.86 Cr settled loans. Its latest AGM occurred on 28 August 2025, with the balance sheet filed on 31 March 2025. It is based at Plot No. P-1 & P-2, It-Bt Park,, Phase-Ii, M.I.D.C., Pune City, Maharashtra, 411057.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    L24231PN1981PLC024251

  • Registration Number

    024251

  • Incorporation Date

    16 April 1981

  • Authorized Capital

    ₹250.00 Cr

  • Paid-Up Capital

    ₹189.57 Cr

  • ROC Code

    Roc Pune

  • Listing Status

    Listed

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 250.00 Cr
  • Paid Up Capital ₹ 189.57 Cr
  • Company Age 44 Year, 10 Months
  • Last Filing with ROC 31 Mar 2025
  • Open Charges ₹ 1,881.89 Cr
  • Satisfied Charges ₹ 7,024.86 Cr
  • Revenue Growth **** 12.48%
  • Profit Growth **** 0.48%
  • Ebitda **** 0.78%
  • Net Worth 5.06%
  • Total Assets **** 3.06%
Company report

Emcure Pharmaceuticals Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Emcure Pharmaceuticals Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Emcure Pharmaceuticals Limited?
Current Directors
Name Designation Appointment Date Status
Shailesh Kripalu Ayyangar Director 16 Apr 2021 Current
Vijay Keshav Gokhale Director 16 Apr 2021 Current
Berjis Minoo Desai Director 03 Apr 1997 Current
Satish Ramanlal Mehta Managing Director 16 Apr 1981 Current
Samit Satish Mehta Whole-Time Director 28 Jul 2022 Current
Sunil Rajanikant Mehta Whole-Time Director 05 Jun 2013 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Alternate Director 24 Feb 2011 Past
Pramod Abcsdd Alternate Director 01 Jun 2009 Past
Pramod Abcsdd Director 28 Feb 2013 Past
Pramod Abcsdd Director 20 Oct 2014 Past
Pramod Abcsdd Company Secretary 01 Sep 2016 Past
Pramod Abcsdd Additional Director 30 Jul 2021 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Emcure Pharmaceuticals.

Emcure Pharmaceuticals Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 12.48% increase. The company also saw a slight improvement in profitability, with a 0.48% increase in profit. The company's net worth moved up by a moderate rise of 5.06%.

Emcure Pharmaceuticals revenue growth over time
Emcure Pharmaceuticals profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 12.48%
*******
*******
*******
*******
Revenue from Operations
*******
 12.57%
*******
*******
*******
*******
Total Assets
*******
 3.06%
*******
*******
*******
*******
Profit or Loss
*******
 0.48%
*******
*******
*******
*******
Net Worth
*******
 5.06%
*******
*******
*******
*******
EBITDA
*******
 0.78%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Emcure Pharmaceuticals?

In 2024, Emcure Pharmaceuticals had a promoter holding of 54.42% and a public holding of 45.57%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹18,818,947,000.00

Satisfied Charges

₹70,248,574,054.00

Charges Breakdown by Lending Institutions
  • Others : 1320.00 Cr
  • Axis Bank Limited : 411.48 Cr
  • Citi Bank N.A. : 150.00 Cr
  • Hdfc Bank Limited : 0.41 Cr
Latest Charge Details
Date Lender Amount Status
18 Dec 2025 Citi Bank N.A. ₹150.00 Cr Open
19 Sep 2025 Others ₹100.00 Cr Open
12 Jun 2025 Others ₹250.00 Cr Open
15 May 2024 Others ₹100.00 Cr Open
04 May 2023 Others ₹175.00 Cr Open

Explore comprehensive loan charge details -

How Many Employees Work at Emcure Pharmaceuticals?

Emcure Pharmaceuticals has a workforce of 6877 employees as of Mar 03, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Emcure Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Emcure Pharmaceuticals's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Emcure Pharmaceuticals
Recent Activity within the Organization
  • Charges

    Progress on A charge with Citi Bank N.A. amounted to Rs. 150.00 Cr with Charge ID 101205811 was registered on 18 Dec 2025. was documented.

  • Charges

    Progress on A charge with Others amounted to Rs. 100.00 Cr with Charge ID 101168650 was registered on 19 Sep 2025. was documented.

  • Annual General Meeting

    Emcure Pharmaceuticals Limited last Annual general meeting of members was held on 28 Aug 2025 as per latest MCA records. was recorded as a recent event.

  • Charges

    The activity A charge with Others amounted to Rs. 250.00 Cr with Charge ID 101117779 was registered on 12 Jun 2025. was completed.

  • Balance Sheet

    The activity Emcure Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Pune. was completed.

  • Charges

    Progress on A charge registered on 19 Nov 2020 via Charge ID 100393737 with Hdfc Bank Limited was fully satisfied on 27 Mar 2025. was documented.

Explore recent activity and updates - View Recent Activity

Recent News, Updates & Announcement

Explore news and more updates - View Recent News

Frequently Asked Questions
What is the CIN of Emcure Pharmaceuticals Limited?

The CIN of Emcure Pharmaceuticals Limited is L24231PN1981PLC024251.

Where is Emcure Pharmaceuticals Limited headquartered?

Emcure Pharmaceuticals Limited is headquartered at Plot No. P-1 & P-2, It-Bt Park,, Phase-Ii, M.I.D.C., Pune City, Maharashtra, 411057.

When was Emcure Pharmaceuticals Limited incorporated?

Emcure Pharmaceuticals Limited was incorporated on 16 April 1981.

Who are the current directors of Emcure Pharmaceuticals Limited?

The current directors of Emcure Pharmaceuticals Limited are

What is the primary industry of Emcure Pharmaceuticals Limited?

The primary industry of Emcure Pharmaceuticals Limited is Manufacturing.

Is Emcure Pharmaceuticals Limited a listed company?

Emcure Pharmaceuticals Limited is listed.

What is the capital structure of Emcure Pharmaceuticals Limited?

The authorized capital of Emcure Pharmaceuticals Limited is ₹250.00 Cr, and the paid-up capital is ₹189.57 Cr.

What is the compliance status of Emcure Pharmaceuticals Limited?

The compliance status of Emcure Pharmaceuticals Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available